GFM
ABCL icon

GF Fund Management’s AbCellera Biologics ABCL Stock Holding History

GF Fund Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.4K Buy
6,696
+814
+14% +$2.93K ﹤0.01% 486
2025
Q4 		$20.1K Sell
5,882
-547
-9% -$2.44K ﹤0.01% 509
2025
Q3 		$32.3K Sell
6,429
-1,134
-15% -$5K ﹤0.01% 435
2025
Q2 		$25.9K Hold
7,563
– – ﹤0.01% 472
2025
Q1 		$16.9K Buy
7,563
+1,361
+22% +$3.9K ﹤0.01% 520
2024
Q4 		$18.2K Buy
+6,202
New +$17.3K ﹤0.01% 482

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GF Fund Management's ABCL Position: Q1 2026 in Review

GF Fund Management increased its AbCellera Biologics (ABCL) stake by 14% in Q1 2026, buying an estimated $2.93K and bringing the position to 6,696 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

GF Fund Management first reported a position in ABCL in Q4 2024 and has held it in 6 quarters since. The position peaked at $32.3K in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • GF Fund Management held 6,696 shares of AbCellera Biologics worth $23.4K as of Q1 2026.
  • GF Fund Management bought 814 AbCellera Biologics shares in Q1 2026, an estimated $2.93K.
  • AbCellera Biologics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #486 holding.
  • GF Fund Management first reported a position in AbCellera Biologics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's AbCellera Biologics position peaked at $32.3K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.